CSTL Stoklara Genel Bakış Bir moleküler tanı şirketi olan Castle Biosciences, Inc. dermatolojik kanserler, Barrett özofagusu, uveal melanom ve ruh sağlığı koşullarının tanı ve tedavisi için test çözümleri sunmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Castle Biosciences, Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Castle Biosciences Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$27.53 52 Haftanın En Yüksek Seviyesi US$35.84 52 Haftanın En Düşük Seviyesi US$16.97 Beta 0.89 1 Aylık Değişim -7.65% 3 Aylık Değişim -8.14% 1 Yıllık Değişim 27.28% 3 Yıllık Değişim -35.35% 5 Yıllık Değişim -19.01% Halka arzdan bu yana değişim 28.64%
Son Haberler & Güncellemeler Daha fazla güncelleme görün
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma Dec 13
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway Dec 12
Castle Biosciences, Inc. Announces the Latest Data from Its Prospective, Multicenter Decide Study Exploring the Impact of Integrating Decisiondx-Melanoma Test Results into SLNB Decision-Making for Patients Recently Diagnosed with Melanoma Nov 07
Castle Biosciences, Inc. Increases Earnings Guidance for the Year 2024 Nov 05
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%? Oct 15
Castle Biosciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 14
Castle Biosciences to Present New Data on Decisiondx-Melanoma and Decisiondx-Um At 21St International Congress of the Society for Melanoma Research Oct 09
Castle Biosciences, Inc.s’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma Sep 30
Castle Biosciences, Inc. Announces the Publication of New Study in Future Oncology Sep 05
Castle Biosciences: Inflection Into Profitability Aug 16
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts Aug 11
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates Aug 08
Castle Biosciences, Inc. Revises Financial Guidance for the Full Year 2024 Aug 06
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up Aug 04
Castle Biosciences, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 16
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment? Jul 12
Castle Biosciences, Inc. Announces that AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher Test Jun 24
Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis Jun 01
Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology May 31
Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival (MFS) in Patients Diagnosed with UM May 10
Consensus estimates of losses per share improve by 28% May 10
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 04
Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024 May 03
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark Apr 30
Founder notifies of intention to sell stock Apr 15
Castle Biosciences, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 12
Castle Biosciences, Inc., Annual General Meeting, May 23, 2024 Apr 11
Independent Chairman of the Board notifies of intention to sell stock Apr 07
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress Apr 05
Castle Biosciences, Inc. Announces Board Changes Mar 28
Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test Mar 08
Founder notifies of intention to sell stock Mar 08
Consensus estimates of losses per share improve by 26% Mar 06
New minor risk - Shareholder dilution Mar 01
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 01
Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024 Feb 29
Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024 Feb 08
Independent Chairman of the Board notifies of intention to sell stock Feb 08
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects Jan 27
Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii Jan 14
Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Jan 08
Forecast to breakeven in 2026 Dec 31
Founder exercised options and sold US$362k worth of stock Dec 13
Independent Chairman of the Board notifies of intention to sell stock Dec 06
Founder notifies of intention to sell stock Nov 24
Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder Nov 10
Consensus estimates of losses per share improve by 21% Nov 09 Castle Biosciences, Inc. Announces New Data Showing the Ability of Its Pipeline Test in Development to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis
New minor risk - Shareholder dilution Nov 04
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 03
Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023 Nov 03
Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans Oct 31
Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Castle Biosciences, Inc. Announces New Study Demonstrating DecisionDx-Melanoma Outperforms a Nomogram Developed at the Memorial Sloan Kettering Cancer Center Oct 06
Castle Biosciences, Inc. Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus Oct 05
Castle Biosciences, Inc. Announces TissueCypher Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus Sep 15
Castle Biosciences, Inc. Announces Data from a Study Showing the Addition of Drug-Drug Interactions and Lifestyle Factors to Drug-Gene Interactions Sep 12
Consensus estimates of losses per share improve by 12% Aug 09
Founder notifies of intention to sell stock Aug 06
Castle Biosciences, Inc. Raises Revenue Guidance for the Full Year 2023 Aug 05
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 03
Independent Chairman of the Board notifies of intention to sell stock Jul 10
Castle Biosciences to Present New DecisionDx®-Melanoma Data at the American Head & Neck Society's 11th International Conference on Head and Neck Cancer Jul 08
Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive Jun 13
Castle Biosciences, Inc. Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging Jun 13
Independent Director recently bought US$69k worth of stock Jun 11
Price target decreased by 11% to US$39.75 Jun 06
Castle Biosciences, Inc. to Share New Data on DecisionDx-Melanoma and DecisionDx-UM at the 2023 ASCO Annual Meeting Jun 04
Consensus EPS estimates fall by 16%, revenue upgraded May 10
Founder notifies of intention to sell stock May 08
Castle Biosciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023 May 05
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 05
Consensus EPS estimates fall by 11%, revenue upgraded Mar 07
Full year 2022 earnings: EPS exceeds analyst expectations Mar 01
Castle Biosciences, Inc. Publishes Data from Prospective, Multicenter Study, Called DECIDE Feb 10
Castle Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 08
Founder notifies of intention to sell stock Feb 05
Castle Biosciences, Inc. Revises Revenue Guidance for the for Full-Year 2022 Jan 09
Founder exercised options and sold US$141k worth of stock Dec 14
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors Nov 16
Founder notifies of intention to sell stock Nov 16
Founder notifies of intention to sell stock Nov 11
Independent Chairman of the Board notifies of intention to sell stock Nov 05
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 03
Castle Biosciences, Inc. Revises Revenue Guidance for the Full Year 2022 Nov 03
Castle Biosciences, Inc. Presents New Data from Collaboration with the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results (SEER) Program Oct 28
Castle Biosciences, Inc. Announces New Data Showing That the Use of Tissuecypher® Barrett’S Esophagus Test Results Can Significantly Improve Management Decisions for Barrett’S Esophagus (Be) Patients with Low-Grade Dysplasia (Lgd)To Improve Health Outcomes Oct 26 Castle Biosciences, Inc. Announces New Data from Prospective, Multicenter DECIDE1 Study Oct 21
Castle Biosciences, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 20
Castle Biosciences, Inc. Announces Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management Oct 14
Castle Biosciences, Inc. to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting Oct 11
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx(R)-Melanoma and Clinicopathologic Factors Provides Optimized, Survival Prognoses for Patients with Cutaneous Melanoma Sep 24
Castle Biosciences, Inc. Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests At Maui Derm Np+Pa Fall 2022 Conference Sep 22
Consensus revenue estimates increase by 10% Aug 15
Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL) Aug 14
Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year 2022 Aug 09
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 09 Hissedar Getirileri CSTL US Healthcare US Pazar 7D -4.6% -4.1% -2.4% 1Y 27.3% -10.2% 23.4%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: CSTL geçen yıl % -10.2 oranında getiri sağlayan US Healthcare sektörünü aştı.
Getiri vs Piyasa: CSTL geçen yıl % 23.4 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı Is CSTL's price volatile compared to industry and market? CSTL volatility CSTL Average Weekly Movement 7.4% Healthcare Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
İstikrarlı Hisse Senedi Fiyatı: CSTL son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: CSTL 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Bir moleküler tanı şirketi olan Castle Biosciences, Inc. dermatolojik kanserler, Barrett özofagusu, uveal melanom ve ruh sağlığı durumlarının tanı ve tedavisi için test çözümleri sunmaktadır. İnvaziv kutanöz melanom tanısı konan hastaların metastaz riskini belirlemek için bir risk tabakalama gen ekspresyon profili (GEP) testi olan DecisionDx-Melanoma'yı; kutanöz skuamöz hücreli karsinomlu hastalar için tescilli bir risk tabakalama GEP testi olan DecisionDx-SCC'yi sunmaktadır; MyPath Melanoma, teşhisi zor melanositik lezyonları olan hastalar için kullanılan bir test; ve TissueCypher, displastik olmayan, belirsiz displazi veya düşük dereceli displazi Barrett özofagusu olan hastalarda gelecekte yüksek dereceli displazi ve/veya özofagus kanseri gelişimini tahmin etmek için uzamsal bir omik test. Ayrıca şirket, uveal melanomlu hastalar için metastaz riskini öngören tescilli bir risk tabakalandırma GEP testi olan DecisionDx-UM testini ve majör depresif bozukluk, şizofreni, bipolar bozukluk, anksiyete bozuklukları, sosyal fobi, obsesif kompulsif kişilik bozukluğu, travma sonrası stres bozukluğu ve dikkat eksikliği hiperaktivite bozukluğu için ilaç tedavisini yönlendirmeye yardımcı olan farmakogenomik bir test olan IDgenetix'i sunmaktadır.
Daha fazla göster Castle Biosciences, Inc. Temel Bilgiler Özeti Castle Biosciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? CSTL temel i̇stati̇sti̇kler Piyasa değeri US$771.04m Kazançlar(TTM ) US$6.08m Gelir(TTM ) US$311.88m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) CSTL gelir tablosu (TTM ) Gelir US$311.88m Gelir Maliyeti US$56.45m Brüt Kâr US$255.43m Diğer Giderler US$249.36m Kazançlar US$6.08m
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/22 11:07 Gün Sonu Hisse Fiyatı 2024/12/20 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Castle Biosciences, Inc. 9 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Catherine Ramsey Schulte Baird Mark Massaro BTIG Kyle Mikson Canaccord Genuity
Göster 6 daha fazla analist 
